A growing number of companies have launched clinical trials for methylenedioxymethamphetamine (MDMA) and its derivatives.
The most recent is Atai Life Sciences, which saw its share price surge 7.71% in mid-day trading to $3.38 after announcing it had launched a Phase 1 study of an MDMA derivative, EMP-01. The study will focus on post-traumatic stress disorder (PTSD).
Last week, MindMed (Nasdaq: MNMD) announced that it had launched a Phase 1 study investigating MDMA-like substances in healthy volunteers.
Potential for PTSD and beyondIn 2020, Multidisciplinary Association for Psychedelic Studies (MAPS) completed a Phase 3 study of MDMA-assisted psychotherapy focused on PTSD. In addition, MAPS has Phase 2 studies underway for eating disorders, anxiety associated with a life-threatening illness and social anxiety in autism.
FDA has granted Breakthrough Therapy Designation to MAPS to test MDMA in PTSD.
Other companies investigating MDMA inclu…